Fédération Nationale des Centres Mémoire de Ressources et de Recherche

DIAGNOSTIC ET PRISE EN CHARGE DE LA MALADIE D’ALZHEIMER ET DES PATHOLOGIES APPARENTEES : RECOMMANDATIONS FEVRIER 2012

[ Chapitre 10 ] - [ Sommaire ] - [ Annexes ]

Références

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9.

Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-21.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. (2009). Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2009; CD001191.

Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database 1515 Syst Rev(1), CD005593.

Birks J, Harvey RJ (2006). Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2006;CD001190.

Choi et al (2011) Tolerability and efficacy of memantine add-on therapy to rivastigmine patches in mild to moderate Alzheimer’s disease : a multicenter, randomized, open- label, parallel-group study . Curr Med Res & opinion 27, 7:1375-1383.

DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20;72(2):245-56.

De Souza, L. C., F. Lamari, et al. (2010). "Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias." Journal of Neurology Neurosurgery and Psychiatry 82 (4)(Mar): 240-6.

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 Aug;6(8):734-46.

Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, et al., Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009 Mar;132(Pt 3):583-91.

Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of Behavioural problems in Alzheimer’s disease. International psychogeriatric, 2010, 2010 May;22 (3):346-72.

Genin, E., D. Hannequin, et al. (2011). "ApoE and Alzheimer's disease: a major gene with semi-dominant inheritance." Mol Psychiatry 16(9): 903-7.

Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008,15;23(15):2248-50.

Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF et al., Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-14.

Huey ED, Putnam KT, Grafman J (2006) A systematic review of neurotransmitter deficits and treatment in frontotemporal dementia. Neurology 66, 17-22.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan;9(1):119-28.

Lebert F, Boitte P, De Bouvet A, Pasquier F. Maladie d’Alzheimer et syndromes apparentés : spécificités des « malades jeunes », reflexions cliniques et ethiques. Geriatr Psychol Neuropsychiatr Vieil. 2012. Sous presse.

Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600-7.

Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;CD001747.

McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Lancet. 2000; 356:2031-6.

Mc Keith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005;65:1863-1872.

McKhann, G., D. Knopman, et al. (2011). "The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup." Alzheimer and Dementia 7 (3)(May): 263-9.

McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154.

Moreaud O, Belliard S, Snowden J, Auriacombe S, Basaglia-Pappas S, Bernard F, et al., Démence sémantique : réflexions d’un groupe de travail pour des critères de diagnostic en français et la constitution d’une cohorte de patients. Rev Neurol. 2008 Apr;164(4):343-53.

Porsteinsson et al (2008)Memantine MEM-MD12 study group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor : a randomized, double blind , placebo-controlled trial ? Curr Alz Res 5 (1) : 83-89 .

Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH Neuhaus J et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134(Pt 9):2456-77.

Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257-68.

Robert P, C.U.Onyike, A.F.G. Leentjens, K. Dujardin, P. Aalten, S.Starkstein, FRJ Verhey, J.Yessavage, J.P.Clement, D. Drapier, F.Bayle, M.Benoit, P.Boyer, PM. Lorca, F.Thibaut, S.Gauthier G.Grossberg, B.Vellas, J.Byrne. Proposed diagnostic criteria for apathy in Alzheimer’s Disease and other neuropsychiatric disease. European Psychiatry, 24, 98 - 104 2009.

Rolland Y, Abellan van Kan G, Nourhashemi F, Andrieu S, Cantet C, Guyonnet-Gillette S, Vellas B. An abnormal "one-leg balance" test predicts cognitive decline during Alzheimer's disease. J Alzheimers Dis. 2009;16:525-31.

Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2) :250-60.

Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, Michel B, Puel M, Volteau M, Touchon J, Verny M, Dubois B. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007 Nov 6;69(19):1859-67.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May ; 7(3) : 280-92.

Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998 Jan;155(1):54-61.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev. 2002 Dec 7;54(12):1567-77.

Tariot PN, Farlow MR, Grossberg GT, et al, for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiv ing donepezil: A randomized controlled trial. JAMA. 2004; 291:317–324.

Villars H, Oustric S, Andrieu S, et al. The primary care physician and Alzheimer's disease: an international position paper. J Nutr Health Aging 2010;14:110-20.

Voisin T, Andrieu S, Cantet C, Vellas B; REAL.FR Group. Predictive factors of hospitalizations in Alzheimer's disease: a two-year prospective study in 686 patients of the REAL.FR study. J Nutr Health Aging. 2010;14:288-91.

Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, et al., Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009 Oct;132(Pt 10):2659-68.


[ Chapitre 10 ] - [ Sommaire ] - [ Annexes ]